Corline Biomedical Valuation
| CLBIO Stock | SEK 6.40 0.14 2.24% |
At this time, the firm appears to be overvalued. Corline Biomedical shows a prevailing Real Value of kr5.99 per share. The current price of the firm is kr6.4. Our model approximates the value of Corline Biomedical from analyzing the firm fundamentals such as Return On Equity of 0.0075, current valuation of 178.43 M, and Profit Margin of 0.02 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Corline Biomedical's price fluctuation is slightly risky at this time. Calculation of the real value of Corline Biomedical is based on 3 months time horizon. Increasing Corline Biomedical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Corline stock is determined by what a typical buyer is willing to pay for full or partial control of Corline Biomedical AB. Since Corline Biomedical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Corline Stock. However, Corline Biomedical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.4 | Real 5.99 | Hype 6.4 | Naive 6.39 |
The intrinsic value of Corline Biomedical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Corline Biomedical's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Corline Biomedical AB helps investors to forecast how Corline stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Corline Biomedical more accurately as focusing exclusively on Corline Biomedical's fundamentals will not take into account other important factors: Corline Biomedical Total Value Analysis
Corline Biomedical AB is currently projected to have takeover price of 178.43 M with market capitalization of 203.87 M, debt of 0, and cash on hands of 41.63 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Corline Biomedical fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
178.43 M | 203.87 M | 0 | 41.63 M |
Corline Biomedical Investor Information
About 55.0% of the company shares are held by company insiders. The book value of Corline Biomedical was currently reported as 4.38. The company had not issued any dividends in recent years. Corline Biomedical had 1196:1163 split on the 4th of January 2021. Based on the analysis of Corline Biomedical's profitability, liquidity, and operating efficiency, Corline Biomedical AB is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Corline Biomedical Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The newest return on assets of Corline implies not a very effective usage of assets in November.Corline Biomedical Ownership Allocation
Corline Biomedical holds a total of 21.49 Million outstanding shares. Corline Biomedical AB retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Corline Biomedical Profitability Analysis
The company reported the revenue of 7.06 M. Net Loss for the year was (6.92 M) with profit before overhead, payroll, taxes, and interest of 9.1 M.About Corline Biomedical Valuation
The stock valuation mechanism determines Corline Biomedical's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Corline Biomedical based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Corline Biomedical. We calculate exposure to Corline Biomedical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Corline Biomedical's related companies.Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. The company was founded in 1991 and is based in Uppsala, Sweden. Corline Biomedical operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 9 people.
8 Steps to conduct Corline Biomedical's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Corline Biomedical's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Corline Biomedical's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Corline Biomedical's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Corline Biomedical's revenue streams: Identify Corline Biomedical's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Corline Biomedical's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Corline Biomedical's growth potential: Evaluate Corline Biomedical's management, business model, and growth potential.
- Determine Corline Biomedical's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Corline Biomedical's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Corline Stock Analysis
When running Corline Biomedical's price analysis, check to measure Corline Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corline Biomedical is operating at the current time. Most of Corline Biomedical's value examination focuses on studying past and present price action to predict the probability of Corline Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corline Biomedical's price. Additionally, you may evaluate how the addition of Corline Biomedical to your portfolios can decrease your overall portfolio volatility.